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Abstract
Background:  Idiopathic pulmonary fibrosis (IPF) is a treatment resistant disease with poor
prognosis. Numerous compounds have been demonstrated to efficiently prevent pulmonary
fibrosis (PF) in animal models but only a few were successful when given to animals with established
fibrosis. Major concerns of current PF models are spontaneous resolution and high variability of
fibrosis, and the lack of assessment methods that can allow to monitor the effect of drugs in
individual animals over time. We used a model of experimental PF in rats and compare parameters
obtained in living animals with conventional assessment tools that require removal of the lungs.
Methods: PF was induced in rats by adenoviral gene transfer of transforming growth factor-beta.
Morphological and functional changes were assessed for up to 56 days by micro-CT, lung
compliance (measured via a mechanical ventilator) and VO2max and compared to
histomorphometry and hydroxyproline content.
Results:  Standard histological and collagen assessment confirmed the persistent fibrotic
phenotype as described before. The histomorphological scores correlated both to radiological (r2
= 0.29, p < 0.01) and functional changes (r2 = 0.51, p < 0.0001). VO2max did not correlate with
fibrosis.
Conclusion: The progression of pulmonary fibrosis can be reliably assessed and followed in living
animals over time using invasive, non-terminal compliance measurements and micro-CT. This
approach directly translates to the management of patients with IPF and allows to monitor
therapeutic effects in drug intervention studies.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive dis-
ease of unknown origin characterized by increased matrix
deposition, resulting in functional impairment and ulti-
mately respiratory failure [1]. Despite considerable
progress in understanding the pathophysiology of this
disease, there is still no efficient treatment [2,3]. Animal
models of pulmonary fibrosis (PF) are critical to investi-
gate pathological mechanisms and are important for pre-
clinical evaluation of novel therapies [4,5]. To date,
several hundreds of compounds were identified in various
models of experimental PF and proposed to have thera-
peutic potential for IPF [5]. However, only a small
number have reached clinical trials and very few have
been assessed in a "true" therapeutic setting [5,6], repro-
ducing the clinical setting where patients with IPF tend to
present late, with advanced fibrotic changes in their lungs
[7]. The vast majority of compounds that were examined
in drug intervention studies in experimental PF are only
successful in a preventive or prophylactic setting, which
means they are given with or prior to administration of
the fibrogenic stimulus [5]. Assessment tools used in
experimental PF are primarily based on histology and
quantitative collagen analysis, providing a snapshot of a
complex and chronic biological process [8], whereas clin-
ical management of IPF relies on physiologic parameters
(lung function, exercise test, echocardiography) and radi-
ology (chest x-ray and high resolution computed tomog-
raphy). Clinical trials are designed to detect changes in
survival and/or lung function parameters [9].
We believe that intervention studies in models of PF
would be more meaningful if the compound was admin-
istered in the fibrotic phase of the disease and not as pre-
vention [8]. The purpose of this study was to characterize
a late-stage non inflammatory model of experimental PF
in detail [10] by comparing conventional assessment
tools to clinically more applicable approaches that do not
require euthanasia. The underlying idea is to establish
reproducible assessment tools for experimental PF in
order to apply these later in drug intervention studies.
Morphological changes were quantified with histomor-
phometry and by analysis of 3D micro-CT images. Lung
function was characterized by measuring lung elastic
recoil and VO2max with treadmill exercise.
The data shows that micro-CT combined with invasive,
non-terminal lung compliance is equally efficient as his-
tomorphometry to generate a fibrotic grading but has the
advantage that it can be done repeatedly in one animal
over time. These evaluation tools directly reflect the clini-
cal management of IPF patients. This approach is adapted
to follow anatomical and functional changes in living ani-
mals over time and is well adapted to perform preclinical
drug evaluation studies.
Methods
Animal treatment
A replication deficient adenovirus carrying active TGF-β1
(AdTGF-β1223/225) was used as previously described [10].
Female Sprague-Dawley rats (200–250 g) received
AdTGF-β1 or control vector AdDl (1 × 108 plaque forming
units/pfu) by intubation. Rats were sacrificed after day 14,
21, 35 and 56 by abdominal aorta bleeding. The animals
were treated according to the guidelines of the Canadian
Council of Animal Care. All animal procedures were per-
formed under inhalation anesthesia with isofluorane
(MTC Pharmaceuticals, Cambridge, Ontario) unless
described otherwise.
Histology
After fixation in 10% buffered formalin for 24 hours,
lungs were paraffin embedded and stained with hematox-
ylin & eosin or picrosirius red. Four axial sections of the
distal left lung were stained with Picro Sirius Red and 20
microscopically fields were examined by three blinded
investigators. Each field was individually assessed for the
severity of PF using Ashcroft's semi quantitative grading
[11].
Hydroxyproline Assay
Hydroxyproline content was determined as described pre-
viously [12]. The results were calculated as μg hydroxypro-
line/mg dry lung weight using hydroxyproline standards
(Sigma Chemicals) and expressed as fold increase over
untreated lung tissue.
Assessment of lung stiffness: flexiVent®
Following anesthesia (Ketamin/Xylazine), animals were
intubated via oropharynx and ventilated (10 ml/kg/
breath). Pressure volume (PV) loops were measured with
flexiVent® (v5.1, Scireq, Montreal, PQ) allowing the rats to
passively expire for 1 sec against 2 cmH2O positive end-
expiratory pressure and then applying 7-step increases
and decreases in volume of 40 ml/kg per step. The param-
eter K of the Salazar-Knowles equation reflects the curva-
ture of the upper portion of the deflation PV curve and
was derived from the PV-loops (v5.1). Lung stiffness was
quantified by fitting the inspiratory limb of the PV loop
and graphed as the volume of air necessary to reach a pul-
monary pressure of 20 cm H2O.
Computed tomography
Micro-CT scan of lungs were obtained using the Micro-CT-
component of an X-SPECT scanner (Gamma Medica-
Ideas, Northridge, California). Rats were anesthetized
using inhalation isofluorane (MTC Pharma, Cambridge,
ON. Canada) in a level II cabinet and inserted in a sealed
Plexiglas's tube with Hepa-filters. All scans were acquired
in spontaneously breathing animals over 512 angles. The
total radiation dose applied to an animal using this tech-Journal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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nique is in the range of 30 mGy, which is similar to lung
CT scans used in clinical medicine [13]. Reconstruction of
the micro-CT images was performed at 155 μm3 voxel
size, converted to Hounsfield Units (HU) selecting air as -
1000 and water as 0 and filtered to reduce noise (sigma =
2 voxel Gaussian 3D filter) using Amira® visualization
software (Mercury Computer Systems). The reconstructed
image was loaded in the segmentation editor of Amira® for
examination. A region-growing tool was utilized to select
trachea, larger airways, normal and fibrotic lung. Three-
dimensional lung surfaces were generated and corre-
sponding density histograms were extracted.
Treadmill and VO2 max
Changes in gas exchange were assessed by maximal oxy-
gen consumption VO2max. Mass-specific oxygen con-
sumption (VO2) and CO2  production (VCO2) was
measured with a flow-through respirometry system (Sable
Systems, Henderson, NV) in a Plexiglas-enclosed motor-
ized treadmill (Columbus Instruments, Columbus,
Ohio). VO2max was measured for each animal, using
three criteria: (i) no change in VO2  when speed is
increased, (ii) rats can no longer keep their position on
the treadmill, and (iii) respiratory quotient (RQ = VCO2/
VO2) > 1.
Statistical analysis
Data are shown as mean ± SEM unless stated differently.
For evaluation of group differences, we used one way
ANOVA with Dunnett's multiple comparison test or stu-
dent's unpaired t test using GraphPad Prism® 5.0. P < 0.05
was considered significant.
Results
Conventional assessment
Histopathology score and collagen quantification
The extent of PF after transfer of active TGF-β1 was
assessed histologically and biochemically and confirmed
findings we reported earlier [10]. Figure 1 shows repre-
sentative images of lung architecture from naïve (A) and
fibrotic lungs from day 14 to 56 (B-E). Peribronchially
accentuated fibrosis, not associated with inflammatory
Representative lung histology Figure 1
Representative lung histology. (A) naïve lungs, (B) day 14, (C) day 21, (D) day 35, (E) day 56 and (F) day 225 after intratra-
cheal AdTGF-β1 administration (40×). (G) Fibrotic index (Ashcroft). (G) Hydroxyproline content per mg dry lung. Group 
comparison was performed using one way ANOVA with Dunnett's multiple comparison test. All values are given as mean, SE, 
n = 4–6 in each group, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. naïve.Journal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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changes and loss of normal lung architecture was
observed up to day 56, as well as subpleural and pleural
thickening (see figure 1D). Persistent fibrosis including
honeycombing was seen in later stages (up to 7 months
after AdTGF-β1) (Figure 1F). Histomorphometric and
hydroxyproline analysis was performed to quantify the
severity of PF up to 56 days after AdTGF-β1 (Figure
1G–H).
Clinical assessment
Image analysis of 3D micro-CT scans
Micro-CT images were acquired over 512 angles, recon-
structed at 155 μm3 voxel (volume-pixel) size and con-
verted to Hounsfield Units (HU) using a Matlab program
where -1000 is defined as the density of air and 0 the den-
sity of water. Axial slices of micro-CT scans of fibrotic
lungs at day 21, 35 and 56 showed areas of denser tissues
compared to naïve lungs (Figure 2A, upper panel), corre-
lating to fibrotic areas in histology slides. Three-dimen-
sional regions were selected and color-coded as follows:
trachea (yellow), normal lung density (blue, -600 to -100
HU), and high lung density (green, -100 to 200 HU). This
allowed visualization of lung areas with different densities
(Figure 2A, medium panel) and quantification after gen-
erating corresponding histograms (Figure 2A, lower
panel). A shift to the right (= denser tissue) was observed
from (see insert) day 21 to 56. Histograms of fibrotic rats
(n = 6) at each time point were selected as described above
and the number of voxels in each bin was subtracted from
a group of unexposed animals. Figure 2B shows the differ-
ential increase and/or decrease of specific voxel ranges
compared to naïve lungs: increase of high dense voxels
corresponding to fibrotic regions (ranging from-100 to
250 HU), and increase of lower density voxels (ranging
from-600 to -400 HU), possibly reflecting airspace
enlargement (e.g. compensatory mechanism or traction
effect) This increase is accompanied by a decrease of nor-
mal density voxels (-200 to -400 HU). A lower magnifica-
tion histology and CT image is provided in Figure 3 which
indicates that this model is persisting up to 225 days after
intratracheal AdTGF-β1 (see Fig 1F for higher magnifica-
tion)
Lung function and VO2max
Rats were intubated via oropharynx and two pressure-vol-
ume (PV) loops were performed for each animal using
flexiVent®. Figure 4A shows the average of all PV-loops at
different time-points. The factor K of the Salazar-Knowles
equation [14] is presented in Figure 4B and demonstrate
a significant decrease which persisted over at least 56 days.
The day before the end of the experiment, rats were placed
on a closed treadmill to run at increasing speeds while
oxygen and C02 were measured continuously. VO2 max
was reduced on average by 10% but this did not reach sta-
tistical significance (data not shown).
Correlation between conventional and clinical assessment
The histomorphology score (Ashcroft) was compared to
lung function, and showed an excellent correlation to the
parameter k (Fig 5A, p < 0.0001). The fibrotic volumes in
micro-CT, defined as high dense voxels comprised
between -100 to +200 HU, correlated both with the
fibrotic score (p = 0.014, Figure 5B) and to the parameter
k (p = 0.035, Figure 5C). There was no correlation to the
decrease in VO2 max (Figure 5D).
Discussion
The purpose of this project was to evaluate non-terminal,
"clinical" assessment tools in an animal model of experi-
mental PF and compare them with standard methods
used in the field. The obvious advantages of non-terminal
tools are that severity and progression of fibrotic changes
or – in the context of drug intervention studies – their
potential reversibility can be followed in individual ani-
mals over time. This reduces variability and the number of
animals that are needed to create relevant time-course
data. In this study, we used an established model of PF
which is based on adenovirus mediated overexpression of
active TGF-β1 in rat lungs [10]. This model incorporates
early fibroproliferation while the transgenic protein is still
expressed, not associated with significant inflammation
(up to 10 days), followed by progressive and persistent
fibrosis, which is driven by endogenous processes, likely
mediated by locally activated TGF-β [10,15].
Current assessment tools for animal models of PF are
based on histology and biochemical analysis of lung tis-
sue [16,17]. It is common practise in experimental models
to use one lung for histology while the other lung is frozen
and homogenized for biochemical and/or molecular
analysis. Histomorphometry is considered as the gold
standard. The method of Ashcroft requires multiple phot-
omicrographs randomly acquired across the lung paren-
chyma and subsequent scoring by several investigators
ranging from 0 to 8, where 8 would be a completely oblit-
erated fibrotic field [11]. We adapted this approach in the
present study with blinded scoring of tissue samples by
three different investigators. This method produces solid
and reproducible data, but it is time consuming and only
a small number of published studies seem to rely on it.
Further, the scoring is usually performed on 20 high-
power magnification images, which only accounts for a
small fraction of the total lung, containing the risk of
selection bias.
The quantification of collagen, or its major amino acid
hydroxyproline, is extensively used in PF models as read-
out for disease severity and success of antifibrotic therapy.
Compounds are considered unsuitable for fibrosis ther-
apy if they have not shown a substantial decrease in lung
hydroxyproline content in an appropriate model. ThereJournal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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Computed tomography Figure 2
Computed tomography. (A). Representative example of one AdTGF-b1 exposed rat, scanned at day 0, 21, 35 and 56. Axial 
slice of CT-scan (upper panel) and 3D reconstructed lungs with fibrotic areas color-coded in green (medium panel). Corre-
sponding histograms of total lung voxels from same animal (lower panel; insert represent percentage of fibrotic tissue. (B). 
Average percentage of voxels different from naïve lungs (All values are given as mean, SE, n = 4 to 6 at each time-point).Journal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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are a number of methodological issues associated with
collagen quantification in the lungs. In experimental PF,
the amount of hydroxyproline rarely exceeds a two-fold
increase over baseline, and the levels are highly variable
[18], narrowing the therapeutic window. This may partly
explain why most published studies use a "prophylactic
setting", giving the drug prior to initiation of fibrosis (usu-
ally by intratracheal bleomycin) [5,19]. With this experi-
mental design it can be assumed that hydroxyproline
levels in drug-treated animals were never increased to a
similar extend as in control animals. This means, the
tested compound interferes with a process that is biologi-
cally different from the one in established fibrosis. Fur-
ther, there is a difference between content and
concentration of lung collagen. In our study we have
quantified hydroxyproline related to dry lung weight to
correct for potential pulmonary fluid accumulation or
edema. Some determine collagen per gram wet weight,
while others present total content per lung independent
of the weight. Finally, it is likely that ultra-structural and
qualitative changes in fibrotic matrix, such as collagen
fiber stiffness or fiber cross-links markedly impact lung
elasticity [20]. These changes cannot be determined by
quantitative analysis of hydroxyproline or histomor-
phometry, but may be captured by physiological measure-
ments.
The routine assessment of IPF patients in clinic includes
measurement of lung volumes, usually forced vital capac-
ity (FVC) and total lung capacity (TLC). These parameters
are difficult to obtain in rodents. In contrast, compliance
can easily be measured and it has been shown that this
parameter of lung stiffness is reduced in IPF patients and
correlates with disease severity [21]. We systematically
performed pressure volume loops in live rats using an
automated ventilator to assess changes in lung elasticity.
The parameter K of the Salazar-Knowles equation, a reflec-
tion of the curvature of the upper portion of the pressure-
volume curve, was reduced by 35 % in animals with PF up
to 56 days after AdTGF-β1. There was a strong correlation
between this "stiffness" parameter and the fibrosis score.
The major advantage of this method is that it can be per-
formed repeatedly in the same animals. We have here
used a rat model of PF, but this method is applicable to
both mice and rats [22-24].
In addition to lung function, human clinical trials are
powered to detect differences in exercise tests, mostly the
6 minute walk [25]. Therefore, we have investigated the
usefulness of VO2max employing a rodent treadmill sys-
tem in a contained Plexiglas tube. VO2max was on average
reduced in fibrotic rats by 10% compared to controls, but
did not allow us to clearly distinguish between the two
groups. It is still unclear why VO2max alterations were less
than expected. The total fibrotic volume defined by CT
scan analysis accounted for 15–20% and it is possible that
this is not sufficient to reduce VO2max significantly. It
may also be that compensatory lung growth and recruit-
ment of alveolar reserves occurs in this rodent model, thus
preventing the progressive functional decline that is so
Correlation Histology – Computed tomography Figure 3
Correlation Histology – Computed tomography. (A). Low magnification histology 225 days after intratracheal AdTGF-
β1 administration (10×) corresponding to CT image of axial slice (B) and to area indicated with red arrow in 3D reconstructed 
lungs from same animal (C). See insert in Fig 1F for higher magnification of same lung.Journal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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Lung function Figure 4
Lung function. (A) Average pressure/Volume curves from naïve and AdTGF-β1 exposed rats. The curves from fibrotic ani-
mals demonstrate marked shifts downward and to the right, indicating stiffer lungs. Note: The upward deviation of the curve at 
day 14 at pressures above 60 cm H2O reflect the upper limits of the pressure transducer. (B) The parameter K was reduced at 
all time-points. (C) Lung stiffness was derived from the PV loop in Figure 4A and characterized as the volume of air needed to 
reach a pressure of 20 cm H2O. All values are given as mean, SE, n = 4–6 per group.Journal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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characteristic for lung fibrosis in humans. Further studies
are required to better understand the complex changes in
cardiopulmonary physiology in animal models of lung
fibrosis. However, the presented data do not support
VO2max as a useful tool for assessment of fibrosis severity
in this model.
Radiologic examination of lungs including high resolu-
tion computed tomography is a mandatory tool to make
Correlations Figure 5
Correlations. Correlations between (A) histological fibrotic score and the parameter K (n = 57), (B) fibrotic score and abso-
lute fibrotic volume (n = 20), (C) parameter K and absolute fibrotic volume (n = 18) and (D) fibrotic score and VO2max (n = 
41).Journal of Translational Medicine 2008, 6:16 http://www.translational-medicine.com/content/6/1/16
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a clinical diagnosis of IPF/UIP [1]. When CT scans are
post-processed, three dimensional structures can be dis-
played with density histograms, making it an ideal candi-
date to follow total lung parenchymal changes over time.
This approach is more widely propagated for chronic dis-
orders characterized by tissue loss such as emphysema
[13,26,27], but may be of significant value in fibrotic lung
disease. Several software packages are commercially avail-
able, allowing extraction of tissue areas of choice which
are defined by certain pre-set parameters. After 3-D recon-
struction, these areas can be measured and the volume of
lung tissue characterized by a specific density range can be
quantified. In CT images, fibrotic lung tissue appears
denser compared to normal lungs. In contrast, a shift
towards lower densities would be associated with air-
space enlargement, emphysema or increase in lung vol-
ume. While it is relatively easy to "virtually dissect" areas
with fibrotic density from normal lung, it is more difficult
to clearly distinguish between fibrosis and mediastinal
structures such as heart, aorta and vena cava. To circum-
vent this, we use a semi-automated 3D extraction of lung
tissues with help of a "segmentation editor" and a "region
growing tool". The volume of fibrotic tissue in our study
was in the range of 10–20% of total lung and correlated
significantly to conventional fibrosis score and lung func-
tion indicating that micro-CT is a promising alternative to
predict lung fibrosis as previously described in the bleo-
mycin model using mice [28] or rats [29]. It is important
to note that this CT technique does not distinguish
between inflammatory and fibrotic changes in the lung
tissue. Other imaging such as PET [30] or MRI [31] tech-
nology might be better suitable to differentiate between
inflammation, edema and fibrosis, which is a relevant
consideration when inflammatory models of fibrosis are
used (e.g. the bleomycin model, in contrast to our non-
inflammatory AdTGF-β1 model).
The major benefit of micro-CT combined with lung com-
pliance over the more traditional tools histology and col-
lagen content is that these assessments can be done
repeatedly throughout the course of an experiment. It is
obvious that validation experiments need to be performed
to demonstrate that these assessments do not interfere
with the progression of experimental disease. Our
approach to future drug efficacy studies with these novel
tools would be to obtain baseline evaluation in each ani-
mal before fibrosis is induced, then confirmation of fibro-
sis before the treatment is initiated and subsequent
evaluation of potential treatment effects. For this purpose,
a minimum number of 3 to 5 animals per group will be
required, depending on the severity of fibrosis and the
magnitude of treatment effects [8]. The overall aim of the
new approach is to directly track if documented fibrotic
changes at one point of the study can be reversed by the
drug intervention at a later time point.
Further, this approach assures that the entire lung is
assessed in each animal, while the conventional tools are
limited by performing histology on one and biochemical
analysis on the other side of the lungs. While we believe
that this novel approach eventually will prove to be supe-
rior compared to terminal assessment in detecting benefi-
cial drug effects, we acknowledge that a series of drug
intervention studies needs to be done to underscore this
hypothesis.
Conclusion
In conclusion, we have translated clinically relevant
assessment tools into an animal model of severe lung
fibrosis and compared them with conventional methods.
We show that the extent of fibrosis can be reliably moni-
tored with small animal CT imaging and lung compliance
measured with a rodent ventilator. These measurements
have the advantage that they can be performed repeatedly
in the same animals over time.
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